Company news
GeoVax Labs, Inc. news in 2026
GeoVax Labs, Inc.'s news releases, calls and decks from 2026, newest first.
Update - GeoVax Enters Into $1 Million Revolving Loan Agreement
October 27, 2026
GeoVax Enters Into $1 Million Revolving Loan Agreement
October 26, 2026
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026
October 6, 2026
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities
September 10, 2026
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation
August 25, 2026
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit
August 20, 2026
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio
August 3, 2026
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update
July 27, 2026
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
July 20, 2026
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
June 7, 2026
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
June 3, 2026
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
May 31, 2026
GeoVax Accelerates Focus on GEO-MVA Commercialization and Advancement of Oncology Program Gedeptin(R)
May 26, 2026
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
May 20, 2026
GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats
May 18, 2026
GeoVax Initiates Phase 3 Execution Activities for GEO-MVA Under EMA-Aligned Immunobridging Pathway
May 5, 2026
GeoVax Advances Gedeptin(R) Toward Phase 2 Initiation and Strategic Partnership Opportunities
April 28, 2026
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update
April 14, 2026
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
April 13, 2026
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
April 1, 2026
GeoVax Announces a Warrant Inducement Transaction
March 30, 2026
GeoVax Provides Update on GEO-MVA Program
March 24, 2026
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients
March 12, 2026
GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine
March 10, 2026
GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid Tumors
February 23, 2026
GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology
February 17, 2026
GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 13, 2026
GeoVax Highlights 2026 as a Pivotal Year for Progress
January 20, 2026
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
January 8, 2026
GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week
January 6, 2026